Robert Safian, MD
Cardiovascular Disease · Royal Oak, MINPI 1588646707
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Medtronic at 58.0% of the total. 2025 is the largest year on record at $13,978, more than ten times the $829 reported in 2019.
Across 92 payments — averaging $278.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Heartflow, Inc.$8K
- Boston Scientific$2K
- Shockwave Medical, Inc$176
- Siemens Medical Solutions USA, Inc.$153
- AstraZeneca$125
- plus $100 from 1 others
What the payments were for
- Consulting fees$8,54433%
- Speaking & faculty fees$4,82519%
- Travel & lodging$7,77630%
- Food & beverage$4,51318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 66 | $14,885 |
| Heartflow, Inc. | 16 | $8,108 |
| Boston Scientific | 4 | $2,111 |
| Shockwave Medical, Inc | 1 | $176 |
| Siemens Medical Solutions USA, Inc. | 1 | $153 |
| AstraZeneca | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,658 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $22,232 |
| Repatha SureclickEvolocumab | 27 | $18,780 |
| Praluent PenAlirocumab | 21 | $11,297 |
| ClopidogrelClopidogrel Bisulfate | 70 | $1,549 |
| Prasugrel Hcl | 14 | $1,379 |
| Ezetimibe | 28 | $805 |
| Atorvastatin Calcium | 32 | $731 |
| Rosuvastatin Calcium | 29 | $592 |
| Metoprolol Succinate | 20 | $458 |
| Carvedilol | 22 | $216 |
| Metoprolol Tartrate | 13 | $153 |
| Amlodipine Besylate | 20 | $133 |
| Lisinopril | 15 | $99 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Royal Oak
- David HainesRoyal Oak$492K
- Douglas HorstmanshofRoyal Oak$407K
- Elvis CamiRoyal Oak$45K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.